Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Neuroendocrine carcinoma (NEC) is an extremely rare subtype of endometrial cancer which is usually seen among perimenopausal or postmenopausal women. It runs an aggressive course and posts a clinical challenge due to limited treatment options available.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Cruz M
Keywords: neuroendocrine carcinoma, endometrium,
#3081 An Atypical Presentation of a Neuroendocrine Carcinoma of Unknown Origin
Introduction: Neuroendocrine carcinomas (NEC) of unknown primary site are uncommon. Most arise from an occult/clinically undetectable primary. Primary NEC of genitourinary tract are rare. High-grade (HG) carcinoms, are rapidly growing and aggressive but usually responsive to platinum-based combination chemotherapy.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Da Silva Dias D, Gosálbez B,
Keywords: .,
Introduction: In spite of new treatments like PRRT or everolimus there is a clinical need for systemic therapies that complement SSAs (somatostatin analogs) and antidiarrheal agents in the treatment of carcinoid syndrome, a late stage problem in s-i-NET. Telotristat is a promising addition to our therapeutic arsenal.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Linder Ekberg K,
Keywords: telotristat, carcinoid syndrome, metastasized GI-NET,
Introduction: G3NEC are heterogeneous and aggressive diseases which can arise in different organs. Platinum-etoposide combination is used as first line treatment whatever the primary. Rb has been suggested to be a predictive/prognostic factor.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Hadoux J
Authors: Hadoux J, Kanaan C, Planchard D, Malka D, Ducreux M,
Keywords: Neuroendocrine carcinoma, Platinum-etoposide, Rb,
Introduction: Rb and p53 status may help distinguishing well from poorly differentiated neuroendocrine neoplasms (NEN) and may predict response to chemotherapy. Studies correlating Rb/p53 genetic and immunohistochemistry were performed on high-quality frozen samples with high throughput techniques efficient for copy number determination. This situation differs from routine practice in which small deletions may be hard to detect on formalin-fixed paraffin-embedded (FFPE) samples with a gene panel approach.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Cros J
Authors: Chen R, Lacroix L, De Rycke O, Lacombe C, Cazes A,
Keywords: rb, p53, aggressive neuroendocrine tumors, biomarker,